Voytas Daniel F 4
4 · Calyxt, Inc. · Filed Feb 26, 2019
Insider Transaction Report
Form 4
Calyxt, Inc.CLXT
Voytas Daniel F
Chief Science Officer
Transactions
- Exercise/Conversion
Common Stock
2019-02-25$3.59/sh+3,977$14,277→ 96,959 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-02-25−3,977→ 208,361 totalExercise: $3.59Exp: 2026-04-07→ Common Stock (3,977 underlying) - Sale
Common Stock
2019-02-25$16.00/sh−3,977$63,632→ 92,982 total
Footnotes (3)
- [F1]Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.
- [F3]The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014 and vested 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vested quarterly in equal installments thereafter, 15% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering.